Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars

Benzinga_recent_news01-08

Aclarion Inc. (NASDAQ:ACON), a commercial-stage healthcare technology company developing biomarker-driven augmented intelligence tools to diagnose chronic low back pain, provided a corporate update on...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601622673?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Muscular-Man-Suffering-From-Back-And-Nec.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-08 21:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601622673","market":"hk","top_or_hot":-1,"title":"Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars","media":"Benzinga_recent_news","content":"<div>\n<p>Aclarion Inc. (NASDAQ:ACON), a commercial-stage healthcare technology company developing biomarker-driven augmented intelligence tools to diagnose chronic low back pain, provided a corporate update on...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-08 21:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aclarion Inc. (NASDAQ:ACON), a commercial-stage healthcare technology company developing biomarker-driven augmented intelligence tools to diagnose chronic low back pain, provided a corporate update on...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACON","symbol_name":"ACLARION, INC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars","article_id":"2601622673","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Muscular-Man-Suffering-From-Back-And-Nec.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/01/49781264/aclarions-ai-back-pain-tech-sees-114-surge-in-demand-stock-soars","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2601622673","pubTimestamp":1767878940,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Aclarion Inc. (NASDAQ: ACON) provided a corporate update on Thursday, reporting strong commercial momentum.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACON":"ACLARION, INC","BK4167":"医疗保健技术"},"translate_title":"Aclarion的人工智能背痛技术需求激增114%，股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACON":1},"content_text":"Aclarion Inc. (NASDAQ:ACON), a commercial-stage healthcare technology company developing biomarker-driven augmented intelligence tools to diagnose chronic low back pain, provided a corporate update on Thursday detailing operating momentum, clinical progress, and financial strength as it enters 2026.\nThe company reported strong adoption of its proprietary Nociscan AI-augmented platform in 2025, with annual scan volumes rising 69% year over year. \nFourth-quarter scan volumes increased 114% from the prior year, marking the third consecutive quarter of growth across U.S., U.K., and European sites. \nDuring the year, Aclarion added nine imaging centers and 22 new physician users, while expanding its commercial and leadership teams in the U.S. and U.K.\nAclarion continued to build clinical and economic evidence supporting Nociscan. The CLARITY trial was launched in 2025 with seven activated sites, positioning the company for future commercial expansion. \nA cost-effectiveness analysis published in ClinicoEconomics and Outcomes Research concluded that Nociscan was more effective and less costly than provocative discography, saving $1,712 per patient and improving surgical success rates by 10%. \nAdditional real-world evidence and a technology overview were published in the International Journal of Spine Surgery.\nLooking ahead, the company aims to enroll approximately 25% of patients in the CLARITY trial by the end of the second quarter of 2026, with an internal interim data readout expected in the third quarter.\nAs of Dec. 31, 2025, Aclarion held $12.0 million in cash and carried no debt, extending its operating runway into the first half of 2027. The company raised more than $22.0 million in equity financing during the year.\n\"We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption,\" CEO Brent Ness said.\nACON Price Action: Aclarion shares were up 55.13% at $8.92 during premarket trading on Thursday, according to Benzinga Pro data.\nImage by Albina Gavrilovic via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601622673","isCrawlerRequest":true}